• The Invisible Infrastructure: Bio-IT World Panel Warns of a Slow-Motion Crisis in Biomedical Data

    Clinical Research News | At last month's Bio-IT World Conference & Expo, Douaa Mugahid, PhD, Data Officer at the Hi-IMPAcTB Consortium at the Harvard School of Public Health moderated a panel of academics, investors, and consultants to take on the future of public data and software infrastructure. It is time to safeguard publicly funded data infrastructure, which underpins virtually all of modern biomedical research.

    Jun 17, 2026

  • A Simple Swab Could Change How Doctors Detect Endometrial Cancer

    Clinical Research News | For the roughly 1.3 to 2 million women who visit their doctor each year with abnormal postmenopausal bleeding, the diagnostic journey has long been an uncomfortable one. The standard workup typically involves an endometrial biopsy—an invasive, often painful procedure that, despite its widespread use, fails to yield a conclusive diagnosis in more than 30% of cases. Two veteran diagnostics executives think there's a better way, and they're betting nearly $45 million in venture funding on it.

    Jun 16, 2026

  • Urine Liquid Biopsy Shows Strong Promise for Guiding Bladder Cancer Treatment — Clinical Trials on the Horizon

    Clinical Research News | A novel urine-based liquid biopsy developed at Stanford University is showing remarkable accuracy in predicting bladder cancer recurrence and may soon reshape how clinical trials enroll and treat patients. The test, developed by urologic oncologist Joseph Liao, M.D., and colleagues, filters out age-related background mutations in urine to produce a cleaner, more reliable signal for detecting residual cancer after surgery and immunotherapy.

    Jun 11, 2026

  • The Scope of Things: Measuring Equity in Cancer Care

    Clinical Research News | In the latest episode of The Scope of Things, Eugene Manley, Jr., founder and CEO of the STEMM & Cancer Health Equity Foundation, explains how underrepresented populations, including Black, Hispanic, Indigenous, rural, low-income, immigrant, underinsured, and uninsured communities, are less likely to receive guideline-aligned biomarker testing and less likely to be asked about clinical trial participation at all.

    Jun 9, 2026